{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:31:50Z","timestamp":1772807510769,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.leukres.2010.05.021","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T08:36:37Z","timestamp":1278491797000},"page":"1410-1416","source":"Crossref","is-referenced-by-count":43,"title":["Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion"],"prefix":"10.1016","volume":"34","author":[{"given":"Pierre","family":"Fenaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfeilst\u00f6cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.leukres.2010.05.021_bib1","first-page":"1400","article-title":"The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England","volume":"91","author":"Phekoo","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2010.05.021_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1586\/era.09.61","article-title":"Azacitidine for the treatment of myelodysplastic syndrome","volume":"9","author":"Cataldo","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1016\/j.leukres.2010.05.021_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MOH.0b013e3283257a74","article-title":"Optimal sequencing of treatments for patients with myelodysplastic syndromes","volume":"16","author":"Itzykson","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.leukres.2010.05.021_bib4","unstructured":"NCCN Clinical Practice Guidelines in Oncology\u2122: Myelodysplastic Syndromes [computer program]. Version 2 2010."},{"issue":"2","key":"10.1016\/j.leukres.2010.05.021_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.leukres.2010.05.021_bib6","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2010.05.021_bib7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2010.05.021_bib8","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood.V90.10.4232","article-title":"International prognostic scoring system and other prognostic systems for myelodysplastic syndromes","volume":"90","author":"Balduini","year":"1997","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2010.05.021_bib9","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.leukres.2010.05.021_bib10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2010.05.021_bib11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/jnci\/djn349","article-title":"Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys","volume":"100","author":"Sekeres","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.leukres.2010.05.021_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01703109","article-title":"The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study","volume":"65","author":"Miller","year":"1992","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.leukres.2010.05.021_bib13","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2010.05.021_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.22779","article-title":"Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes","volume":"110","author":"Knipp","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2010.05.021_bib15","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood.V91.8.2985.2985_2985_2990","article-title":"Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression","volume":"91","author":"Quesnel","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2010.05.021_bib16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood-2008-06-163246","article-title":"Aberrant DNA methylation is a dominant mechanism in MDS progression to AML","volume":"113","author":"Jiang","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2010.05.021_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-134-7-200104030-00011","article-title":"Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications","volume":"134","author":"Santini","year":"2001","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.leukres.2010.05.021_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1586\/ehm.09.6","article-title":"Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes","volume":"2","author":"Santini","year":"2009","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"10.1016\/j.leukres.2010.05.021_bib19","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/1535-7163.MCT-08-0411","article-title":"Azacytidine causes complex DNA methylation responses in myeloid leukemia","volume":"7","author":"Stresemann","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.leukres.2010.05.021_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2010.05.021_bib21","unstructured":"Celgene Europe Ltd. Vidaza\u00ae Summary of product characteristics; 2008."},{"issue":"10","key":"10.1016\/j.leukres.2010.05.021_bib22","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.leukres.2010.05.021_bib23","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.021_bib24","first-page":"2524","article-title":"Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients \u226565 years of age","volume":"106","author":"Silverman","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"10","key":"10.1016\/j.leukres.2010.05.021_bib25","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.021_bib26","doi-asserted-by":"crossref","unstructured":"Seymour JF, Fenaux P, Silverman LR, Mufti SJ, Hellstr\u00f6m-Lindberg E, Santini V, et al. Effects of azacitidine compared with conventional care regimens in elderly (\u226575 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; in press.","DOI":"10.1016\/j.critrevonc.2010.04.005"},{"issue":"4","key":"10.1016\/j.leukres.2010.05.021_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2010.05.021_bib28","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2008.17.1058","article-title":"Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes","volume":"27","author":"Lyons","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2010.05.021_bib29","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.05.021_bib30","first-page":"3797","article-title":"A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS)","volume":"114","author":"Sekeres","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"10.1016\/j.leukres.2010.05.021_bib31","first-page":"117","article-title":"A Phase 1, Open-Label, Dose-Escalation Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)","volume":"114","author":"Garcia-Manero","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2010.05.021_bib32","first-page":"227","article-title":"The effects of continued azacitidine (AZA) treatment cycles on response in high-risk patients (Pts) with myelodysplastic syndromes (MDS)","volume":"112","author":"Silverman","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl","key":"10.1016\/j.leukres.2010.05.021_bib33","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/jco.2008.26.15_suppl.7006","article-title":"Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission","volume":"26","author":"List","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.leukres.2010.05.021_bib34","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/jco.2008.26.15_suppl.7028","article-title":"Patient outcome measures during prolonged survival in patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)","volume":"26","author":"Santini","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.leukres.2010.05.021_bib35","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1038\/sj.leu.2403934","volume":"19","author":"Zwierzina","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.05.021_bib36","unstructured":"Santini V, Fenaux P, Mufti GJ, Hellstr\u00f6m-Lindberg E, Silverman LB, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol; in press."},{"issue":"4","key":"10.1016\/j.leukres.2010.05.021_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-009-0824-5","article-title":"Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil","volume":"89","author":"Platzbecker","year":"2010","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.leukres.2010.05.021_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.leukres.2010.05.021_bib39","first-page":"223","article-title":"Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS\u2013AML) in complete remission (CR) after induction chemotherapy","volume":"112","author":"Gr\u00f6vdal","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2010.05.021_bib40","first-page":"844","article-title":"A Phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and high-risk MDS: a GFM Group study","volume":"114","author":"Gardin","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2010.05.021_bib41","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination study of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.05.021_bib42","first-page":"224","article-title":"Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2010.05.021_bib43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/cncr.24894","article-title":"Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program","volume":"116","author":"Musto","year":"2010","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610002808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T17:55:05Z","timestamp":1591466105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610002808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0145212610002808"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.05.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}